Broncus Holding (HKSE:02216) Stock Based Compensation : HK$1.84 Mil (TTM As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Broncus Holding Stock Based Compensation?

Broncus Holding's Stock Based Compensation for the six months ended in Dec. 2024 was HK$0.97 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 was HK$1.84 Mil.

Broncus Holding Stock Based Compensation Historical Data

The historical data trend for Broncus Holding's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Broncus Holding Stock Based Compensation Chart

Broncus Holding Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Stock Based Compensation

Get a 7-Day Free Trial

3.95

70.28

8.74

4.34

1.84

Broncus Holding Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Stock Based Compensation	Get a 7-Day Free Trial						1.36	3.45	0.91	0.87	0.97

Broncus Holding Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$1.84 Mil.

Broncus Holding Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Broncus Holding's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.

Broncus Holding Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Broncus Holding Corp (HKSE:02216) » Definitions » Stock Based Compensation

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 88 Jiangling Road, Xixing Street, Room 801, 8th Floor, Building 8, Binjiang District, Hangzhou, CHN

Website

https://www.broncus.com

Broncus Holding Corp is focused on provision of interventional treatment of Chronic Obstructive Pulmonary Disease and lung cancer. It engages in the field of Interventional Pulmonology, providing solutions for lung diseases in China and globally. Its products portfolio includes the InterVapor Thermal Vapor Treatment System the only implantable medical device to treat COPD; BroncAblate Radiofrequency Ablation System the transbronchial interventional treatment product for lung cancer; Targeted Lung Denervation Radiofrequency Ablation System the self-developed targeted radiofrequency ablation system in China to reduce the risk of acute exacerbation of COPD.

Executives

Computershare Hong Kong Trustees Limited	2301 Trustee
Zi Zhenjun
Xu Hong	2101 Beneficial owner
Xin Nuo Tong Investment Limited	2201 Interest of corporation controlled by you
Qiming Corporate Gp Iv, Ltd.	2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p.	2101 Beneficial owner
Qiming Gp Iv, L.p.	2201 Interest of corporation controlled by you
Dinova Capital Limited
Dinova Venture Partners Gp Iii, L.p.
Broncus Biomedical Limited
Dinova Healthcare Gamma Fund (usd) L.p.
Qm12 Limited	2101 Beneficial owner
Dinova Healthcare (hong Kong) Co., Limited
Lake Bleu Capital (hong Kong) Limited	2102 Investment manager
Hang Zhou De Nuo Shang Wu Zi Xun Zi Xun You Xian Gong Si

Broncus Holding Headlines

No Headlines